Abstract
Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Current Molecular Medicine
Title:Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Volume: 14 Issue: 7
Author(s): P. Vanichakarn, J. Hwa and J. Stitham
Affiliation:
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Abstract: Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Export Options
About this article
Cite this article as:
Vanichakarn P., Hwa J. and Stitham J., Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115517
DOI https://dx.doi.org/10.2174/1566524014666140811115517 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AT1 Receptor Antagonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Dosing of Antibiotics in Critically Ill Patients Undergoing Renal Replacement Therapy
Current Pharmaceutical Biotechnology Acute Actions of Natriuretic Peptides in Coronary Vasculature and Ischaemic Myocardium
Current Pharmaceutical Design Epigenetic Regulation Through SIRT1 in Podocytes
Current Hypertension Reviews Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial from Guest Editor [Hot Topic: Mechanical Ventilation in Pediatrics and Neonatology (Guest Editor: Werther Brunow de Carvalho)]
Current Respiratory Medicine Reviews Chronotherapeutic Drug Delivery Systems - An Approach to Circadian Rhythms Diseases
Current Drug Delivery Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Application of Central Composite Design in Optimization of Valsartan Nanosuspension to Enhance its Solubility and Stability
Current Drug Delivery Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews Editorial from Editor-in-Chief (Adherence to CPAP: Understanding the Key to a Successful Treatment)
Current Respiratory Medicine Reviews Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets
Current Drug Targets Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued)